FDG PET Imaging for Gynecological Cancer

PET/CT is approved by Medicare for use in staging of cervical cancer and restaging of ovarian cancer.
Lin et al (2003) found that the sensitivity and specificity of PET in the detection of para aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings were 94% and 86% respectively (1)

Torizuka et al. (2002) found that PET had a sensitivity and specificity in detecting ovarian cancer of 80% and 100% compared to 55% and 100% for conventional imaging. (2)

1. Lin et al, “Usefulness of FDG PET tomography to detect para aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings.” Gynecologic Oncology 89 (2003) 73-76.
2. Torizuka et al., Ovarian cancer recurrence: role of whole body PET using FDG. European Journal of Nuclear Medicine Vol. 29, No. 6 June 2002

Case Study

Patient: 60yo female initially diagnosed with ovarian cancer 1 year ago. Patient presents with abdominal pain and negative CT. PET/CT was ordered to detect recurrence.

Results: PET/CT found anatomically occult hypermetabolic foci consistent with a recurrent ovarian cancer. The patient was treated with chemotherapy sooner than she would have been based on anatomical imaging